B-cell Acute Lymphocytic Leukemia

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

By

FDA approval was based on results of the single-arm phase 2 JULIET clinical trial.

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

By

The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs